Vaccinex, Inc. Stock News
$0.70
0.14%
Nasdaq, Oct 23, 11:03 am EDT.
Closed.
Vaccinex, Inc. Stock News
ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced the publication in Nature Communications of results from an Emory University and Winship Cancer Institute-sponsored pilot study evaluating p...
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
